Slayback Pharma intros generic Makena

1/22/2019
Slayback Pharma is debuting its first commercial product with the launch of its generic Makena injection (hydroxyprogesterone caproate injection 1,250 mg/5 ml).

Slayback’s generic Makena also is the first generic of Amag Pharmaceuticals’ drug in a multidose vial. The 5 ml multidose vial contains the drug with a 250 mg/ml dosage strength. It is indicated to reduce the risk of preterm birth in women with a singleton pregnancy and a history of singleton spontaneous preterm birth.

The drug had a market size of roughly $323 million for the 12 months ended July 2018, according to IQVIA data.

Though the first with a multidose vial, Slayback is the second company to hit the market with a generic Makena — Amneal and American Regent teamed up on the launch of American Regent’s preservative-free, single-dose generic in September. Under the five-year agreement, Amneal will market the product to retail consortiums and American Regent will handle marketing to specialty and hospital channels.
X
This ad will auto-close in 10 seconds